Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia® Genomic Classifier.

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Two Investor Conferences

Veracyte to Present at Two Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Promotion of Richard T.

Veracyte Announces Promotion of Richard T. Kloos, M.D.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Initiates Study to Generate Consensus on Medical Utility of Multiple Breast Cancer Genomic Tests

Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announces positive clinical utility data for Percepta classifier published online in CHEST

Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST

Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q2 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Second Quarter 2020 Financial Results

Veracyte Announces Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Data Published in AJRCCM Showing that the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery

Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary

Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary

Veracyte sees its Relative Strength Rating move into the 80-plus level.
The post Veracyte Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Veracyte Clears Technical Benchmark, Hitting 80-Plus RS Rating

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020

Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020

A Relative Strength Rating upgrade for Veracyte shows improving technical performance. Will it continue?

Veracyte Earns Relative Strength Rating Upgrade To 80

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q1 2020 Results - Earnings Call Transcript

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veracyte (VCYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Veracyte (VCYT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Veracyte (VCYT) Stock Might be a Great Pick

Stock Upgrades: Veracyte Shows Rising Relative Strength

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q4 2019 Results - Earnings Call Transcript

Exact Sciences

Genome testing is exploding on a global level; these companies are saving lives and making money.

2 Top Genome Testing Stocks for Your Watch List

Veracyte, Inc.: An Undervalued Odds-On Near-Term Capital-Gainer

Veracyte: Adding Another Big Pharma Partner Backs Bullish Outlook

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Illumina

Intellia Therapeutics

Invitae

REGENXBIO

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

News for Veracyte Stock (VCYT)